AbCellera - ABCL Enterprise Value-to-Revenue Ratio

AbCellera (ABCL) - corporate logo

AbCellera Biologics (ABCL) brings together leading immunologists and AI engineers, creating a synergy of science and Silicon Valley technology. The EV/Sales ratio demonstrates the balance between business value and revenue, with 40732.24 representing the current level of the metric. Revenues are based on licenses and royalties from global pharma behemoths, while the proprietary platform provides a significant technological barrier for competitors.

AbCellera (ABCL) EV/Sales Multiple: for the period 11/23/2025 - 11/20/2026

ABCL (AbCellera Biologics Inc): analytical breakdowns and indicator data

- current quotes and average value forecast:
Fundamental company valuation:ABCL, AbCellera Biologics
Flagship merchandise of AbCellera Biologics Inc.

Capital is seeking to differentiate stable assets from speculative instruments. The reliability of AbCellera Biologics (ABCL) is bolstered by the architectural independence of cloud computing for AI-driven antibody analysis. This EV/Sales multiple chart reflects the enterprise value relative to revenue, measuring the market premium for every dollar of sales. The stabilization of this curve signals that a temporary equilibrium has been reached. However, a prolonged sideways trend may indicate a decline in operational momentum.

Competitor analysis

ARGX - EV/Sales Multiple|BNTX: EV/Sales Multiple|ABVX (Abivax SA) - Enterprise Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio ADMA Corp|Enterprise Value-to-Revenue Multiple Protagonist Therapeutics PTGX|Company Value to Revenue IMVT (Immunovant Therapeutics)|Total Company Value-to-Revenue Ratio kiniksa.com|Enterprise Value-to-Revenue Ratio Grifols Biemat GRFS|Enterprise Value-to-Revenue Coefficient ADPT (Adaptive Biotechnologies Corporation)|celldex.com - EV/Sales Multiple|Total Company Value-to-Revenue Ratio Aurinia Pharma AUPH|biocryst.com (BCRX) - Enterprise Value-to-Revenue Ratio|Vera Therapeutics, Inc. - Business Value to Revenue|Enterprise Value-to-Revenue Ratio Dianthus Therapeutics Inc|Pharvaris NV (PHVS) - Total Company Value-to-Revenue Ratio|Enterprise Value-to-Revenue Ratio Tourmaline Bio, Inc. (TRML)|PGEN (Intrexon) - Business Value to Revenue|EV/Sales Multiple PHAR (Pharming Corp)|nektar.com (NKTR) - Enterprise Value-to-Revenue Multiple|UPB - Enterprise Value-to-Revenue Ratio|Business Value to Revenue ZBIO (Zenas Biopharma)|IMNM: EV/Sales Multiple|Enterprise Value-to-Revenue Multiple Gossamer Bio, Inc. (GOSS)|Enterprise Value-to-Revenue Ratio KalVista Pharmaceuticals|Septerna Inc (SEPN) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple PVLA|SVRA (Savara) - Business Value to Revenue|Rigel Pharma - Company Value to Revenue|Total Company Value-to-Revenue Ratio AnaptysBio Corp (ANAB)|ATXS: Company Value to Revenue|Business Value to Revenue ENGN (enGene Holdings Inc.)|RAPT Therapeutics Inc. (RAPT) - Enterprise Value-to-Revenue Ratio|Aerovate Therapeutics Inc (JBIO) - EV/Sales Multiple|ACRS (Aclaris Therapeutics, Inc) - EV/Sales Multiple|Kyverna (KYTX) - Total Company Value-to-Revenue Ratio|EV/Sales Multiple TLSA|Company Value to Revenue Cabaletta Bio, Inc. CABA|Ventyx Biosciences - Company Value to Revenue|THTX: Company Value to Revenue Ratio|AVTX - Enterprise Value-to-Revenue Ratio|ELDN: Enterprise Value-to-Revenue Ratio|Agenus Inc. (AGEN) - Enterprise Value-to-Revenue Ratio|Company Value to Revenue Climb Bio Inc|ZURA (Zura Bio Ltd) - EV/Sales Multiple|EV/Sales Multiple aTyr Pharma Inc|EV/Sales Multiple ADAG|Total Company Value-to-Revenue Ratio ImageneBio|EV/Sales Multiple STTK (Shattuck Labs Inc)|EV/Sales Multiple Equillium, Inc. EQ|CNTB - Enterprise Value-to-Revenue Ratio|Immunic Therapeutics (IMUX) - Company Value to Revenue|ATRA: EV/Sales Multiple|InflaRx GmbH (IFRX) - EV/Sales Multiple|XFOR (x4pharma.com) - EV/Sales Multiple|EV/Sales Multiple Adicet Bio|Enterprise Value-to-Revenue Ratio Celularity Inc (CELU)|Company Value to Revenue INmune Bio Corp INMB|Enterprise Value-to-Revenue Ratio Barinthus Biotherapeutics plc BRNS|KZR - Company Value to Revenue|sabbiotherapeutics.com - EV/Sales Multiple|akaritx.com (AKTX) - Company Value to Revenue|ENLV: EV/Sales Multiple|QTTB (Q32 Bio Inc) - Enterprise Value-to-Revenue Ratio|GOVX (geovax.com) - EV/Sales Multiple|EV/Sales Multiple Edesa Biotech Corp|EV/Sales Multiple IBIO|Company Value to Revenue Carisma Tx CARM|Enterprise Value-to-Revenue Ratio XTL Biopharmaceuticals Ltd XTLB|EV/Sales Multiple Bolt Biotherapeutics BOLT|HCW Biologics - EV/Sales Multiple|Enterprise Value-to-Revenue Multiple aptevotherapeutics.com|AIM (AIM ImmunoTech, Inc.) - Company Value to Revenue|Aditxt Corp - Business Value to Revenue|GRI (GRI Bio Inc) - EV/Sales Multiple|EV/Sales Multiple XORTX Therapeutics Inc|Enterprise Value-to-Revenue Ratio Vyome Therapeutics (HIND)|REVB - Enterprise Value-to-Revenue Multiple|Enterprise Value-to-Revenue Ratio Indaptus Therapeutics, Inc. INDP|EV/Sales Multiple scinai.com SCNI|CalciMedica Inc - EV/Sales Multiple|AFMD - EV/Sales Multiple|ALLK: EV/Sales Multiple|Enterprise Value to Sales Volume HOOK (HOOKIPA Pharma, Inc.)|IGMS (IGM Biosciences) - EV/Sales Multiple|ITOS: Business Value to Revenue|Company Value to Revenue OCEA (Ocean Biomedical)|TCBP: Enterprise Value to Sales Volume|Enterprise Value-to-Revenue Ratio Third Harmonic Bio Inc THRD